Monitoring activity of fibrinolytic agents. A therapeutic challenge.
The recognition that thrombolytic therapy may be beneficial for coronary thrombolysis has led to an increased use of plasminogen activators in critically ill patients, sometimes with inadequate monitoring. This review delineates the components of the fibrinolytic system, describes mechanisms of fibrinolysis, and presents practical guidelines for monitoring the use of activators of the system.
D001778:Blood Coagulation Disorders / Q000188:drug therapy; D004334:Drug Administration Schedule; D005338:Fibrin Fibrinogen Degradation Products / Q000494:pharmacology; D005341:Fibrinolysin / Q000037:antagonists & inhibitors / Q000502:physiology; D005342:Fibrinolysis / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D010314:Partial Thromboplastin Time; D010960:Plasminogen Activators / Q000502:physiology; D011517:Prothrombin Time; D013300:Streptokinase / Q000494:pharmacology; D013918:Thrombin Time; D014568:Urokinase-Type Plasminogen Activator / Q000494:pharmacology
D005338:Fibrin Fibrinogen Degradation Products; D005343:Fibrinolytic Agents; D013300:Streptokinase; D010960:Plasminogen Activators; D005341:Fibrinolysin; D014568:Urokinase-Type Plasminogen Activator